CTLA4 and cancer: Moreover, based on the relative absence of autoimmunity in LAG-3 KO mice, Durman et al. suggested a possible clinical advantage of LAG-3 blockade versus, for instance, CTLA-4 blockade in terms of decreased toxicity, thus rendering LAG-3 a suitable partner to block in cancer combination immunotherapy [43].